The Cancer Research Collaboration was honored to receive a donation from the Tzedakah Board at Tarbut V' Torah Community Day School, made up of Bar and Bat Mitzvah students. Every year, instead of giving gifts to one another, they celebrate by pooling their money and donating it to charity, to make a difference in the world. This year, they raised over $3700.
On behalf of Kia of Cerritos, Deb McMahon and Teresa Kelly presented a check for $10,000 to Kristi Maya and Terri Herrick of the Cancer Research Collaboration. Deb and Teresa’s firm represent Kia of Cerritos and brought the two organizations together. Kia was excited to work with the Cancer Research Collaboration, knowing that they partnered with Breastlink to conduct trials, particularly breast cancer. Breast cancer is an important cause to the Kia owners and to show their support, they pledged 10 percent of each car they sold during Breast Cancer Awareness Month to the CRC.
While news about an album release may seem surprising on a cancer research blog, the third album from Los Angeles-based singer-songwriter Raven Quinn is a little different. The Acoustic EP is the first album released by Raven Quinn since she was diagnosed with breast cancer in June 2015. Additionally, Raven will donate one-half of all proceeds from album sales to the Cancer Research Collaboration.
Women with advanced estrogen receptor-positive (ER-positive) breast cancer now have a new treatment option at their disposal. The FDA recently approved a drug called palbociclib (Ibrance®) as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.
First Annual CRC Charity Golf Tournament
The Importance of Breast Cancer Research: proceeds of the first Cancer Research Collaboration Charity (CRC) Golf Tournament will be used to support ongoing efforts of the CRC and its partners to fight cancer.
Recent research into modern breast cancer therapies have driven major breakthroughs in antibody-drug conjugates, or “smart drugs,” which work by targeting cancer cells while minimizing damage to healthy body tissue.
Kadcyla, also known ado-trastuzumab emtansine (T-DM1), is one of the latest “smart drugs” to be FDA-approved in the treatment of women diagnosed with metastatic HER2-positive breast cancer. Kadcyla may also have potential as therapy after surgery where intent is curative.
RadNet Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, announced it has joined a research study, the Imaging and Genetic Biomarkers for Alzheimer’s Disease (ImaGene) study.
Kadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer.